DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the NK Cell Therapy Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NK Cell Therapy NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the NK Cell Therapy Pipeline Insight Report
- Over 100+ NK Cell Therapy companies are evaluating 185+ NK Cell Therapy therapies in various stages of development, and their anticipated acceptance in the NK Cell Therapy market would significantly increase market revenue.
- The leading NK Cell Therapy Companies include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, and others.
- Promising NK Cell Therapy Pipeline therapies include Allogeneic NK cells, FATE-NK100, Cetuximab, Trastuzumab, FT500, Nivolumab, Pembrolizumab, Immune Killer Cells (IKC), brentuximab vedotin, cyclophosphamide, prednisone, Cytarabine, Daunorubicin, Etoposide, SNK01, Avelumab, Pembrolizumab, CYNK-001, and others.
- The NK Cell Therapy Companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK) cell therapy R&D. The NK Cell Therapy pipeline therapies under development are focused on novel approaches to treat/improve Natural Killer (NK) cell therapy.
To explore more information on the latest breakthroughs in the NK Cell Therapy Pipeline Treatment landscape of the report, click here @ NK Cell Therapy Pipeline Outlook
NK Cell Therapy Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias.
Latest Developmental Activities in the NK Cell Therapy Treatment Landscape
- In February 2021, Nektar has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase II/III study of Bempegaldesleukin.
- In December 2017, Five Prime and Zai Lab announced a strategic collaboration for the development and commercialization of bemarituzumab in Greater China.
- In August 2019, Nektar Therapeutics and Bristol-Myers Squibb announced that the US FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
For further information, refer to the detailed NK Cell Therapy Unmet Needs, NK Cell Therapy Market Drivers, and NK Cell Therapy Market Barriers, click here for NK Cell Therapy Ongoing Clinical Trial Analysis
NK Cell Therapy Emerging Drugs Profile
NKTR-214: Nektar therapeutics
Nectar Therapeutics is developing NKTR-214 which is an intravenously administered, investigational, engineered IL-2 cytokine for the treatment of solid tumors. NKTR-214 is a prodrug, as it is delivered to the body in an inactive form. The body breaks down the prodrug to produce a signaling molecule that is biased toward binding to and activating CD122, a subunit of IL-2R. When NKTR-214 binds to CD122, it triggers an increase in the number of TILs. In August 2019, Nektar Therapeutics and Bristol-Myers Squibb announced that the US FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma. In February 2021, Nektar has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase II/III study of Bempegaldesleukin.
Monalizumab: Innate Pharma
Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.
Bemarituzumab: Five Prime Therapeutics
Bemarituzumab is a first-in-class, isoform-selective, humanized monoclonal antibody in clinical development as a targeted immunotherapy for tumors that overexpress FGFR2b, a splice variant of a receptor for some members of the fibroblast growth factor (FGF) family. Bemarituzumab blocks FGFs 7, 10, and 22 from binding to FGFR2b, and has been engineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting natural killer (NK) cells. Clinical results to date suggest that the specificity of bemarituzumab avoids the dose-limiting toxicities that have been noticed with less selective pan-FGFR tyrosine kinase inhibitors that act on multiple FGFRs, including FGFR2. In December 2017, Five Prime and Zai Lab announced a strategic collaboration for the development and commercialization of bemarituzumab in Greater China.
ALT 803: ImmunityBio
ALT 803 is a novel IL-15 superagonist complex, with improved pharmacokinetic properties and enhanced anti-tumor activity compared to recombinant human IL-15. It has also shown to potently activate human effector NK cells and enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-CD20 antibodies against human lymphoma cells in various tumor models. It is under development by Altor Bioscience Corporation and is currently in Phase II/III for Bladder Cancer. It is in Phase II stage for the treatment of Acute Myelogenous Leukemia (AML); Non-muscle Invasive Blood Cancer, in Phase I/II stage for the treatment of Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndromes (MDS); Multiple Myeloma; Advanced Pancreatic Cancer; Non-small Cell Lung Cancer and Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma. It is in Phase I stage for the treatment of Human Immunodeficiency virus (HIV) and Melanoma, Renal Cell, and Squamous Cell Head and Neck Cancer. It is developed by using IL-15 Protein Super agonist and Scaffold Technology and is administered by intravenous route.
CellProtect: XNK Therapeutics
CellProtect is a novel cell therapy based on autologous NK cells that are expanded and their cytotoxic activity restored through a patented process. The cells are then infused into the patient to treat the disease. Cell Protect is under development by CellProtect Nordic Pharmaceuticals and is currently in Phase II stage for the treatment of Multiple Myeloma at the Karolinska University Hospital in Huddinge, Sweden and Sanofi’s support by providing Sarclisa. It is manufactured under GMP conditions at the core facility Vecura at Karolinska University Hospital.
K-NK002: Kiadis Pharma
NK002 is a natural killer cell-based immuno-oncology therapy. The molecule is made up of company’s proprietary off-the-shelf NK-cell platform. K-NK002 is an NK cell product derived from peripheral blood leukocytes collected from a related donor (HLA-haploidentical matched) and enriched for NK cells with depletion of CD3+ T-lymphocytes (T-cells) followed by enriched ex-vivo expansion. K-NK002 is under Phase II clinical development by Kiadis Pharma for the treatment of acute myeloid leukemia and Myelodysplastic syndromes. CytoSen’s lead NK-cell therapy candidate, CSDT002-NK is now known as K-NK002 after the company being acquired by Kiadis Pharma in 2019
NK-92: ImmunityBio
NK-92 also known as aNK is activated natural killer (NK) cells and administered intravenously. It is the only cell line that can be commercialized as a direct, scalable and off-the-shelf product, which attacks and kills abnormal cells on contact. NK-92 does not require an intact immune system for killing the diseased cells in the body. It targets NK ligand and activates its action. NK-92 cells are also being engineered to target specific cancers and also to express a receptor that will couple with monoclonal antibodies to enhance their cancer-killing effects. NK-92 is being evaluated in Phase II stage of development for the treatment of stage IIIB & IV Merkel cell carcinoma as monotherapy and in combination with ALT-803, in Phase I stage of development for acute myeloid leukemia, Hematological Malignancies and solid tumors and in the Pre-IND phase for hepatocellular carcinoma and infectious disease.
WU-NK-101: Wugen
WU-NK-101 is a cytokine-induced memory-like NK cell product derived from leukapheresed allogeneic donor NK cells. The drug is in Phase II clinical development studies for acute myelogenous leukemia (AML) and myelodysplastic syndromes treatment. In an ongoing Phase I/II clinical trial, WU-NK-101 had demonstrated an impressive complete response rate in relapsed/refractory AML.
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Anti-CD33 CAR-NK cells is novel specific chimeric antigen receptor NK cells with specificity for CD33 antigen receptor. The allogenic NK cell lines (NK-92 cell lines for clinical use) are engineered to contain anti-CD33 which is attached to TCRzeta, CD28, and 4-1BB signaling domains. The cell line immunotherapy is developed by PersonGen Biotherapeutics using its CART- NK- cell amplification Technology. The modified cell lines have specificity for CD 33 antigen after infusion which can be used in the treatment of Acute Myeloid Leukemias. The company is evaluating the feasibility of CAR-pNK cell line immunotherapy in Phase I/II clinical trials for CD 33 Positive Relapsed or Refractory Acute Myeloid Leukemias.
ALECSAT: CytoVac
ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patient’s immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II stage of development.
NK Cell Therapy Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.
Request a sample and discover the recent advances in NK Cell Therapy Ongoing Clinical Trial Analysis and Medications, click here @ NK Cell Therapy Treatment Landscape
Scope of the NK Cell Therapy Pipeline Report
- Coverage- Global
- NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, and others.
- NK Cell Therapy Pipeline therapies- Allogeneic NK cells, FATE-NK100, Cetuximab, Trastuzumab, FT500, Nivolumab, Pembrolizumab, Immune Killer Cells (IKC), brentuximab vedotin, cyclophosphamide, prednisone, Cytarabine, Daunorubicin, Etoposide, SNK01, Avelumab, Pembrolizumab, CYNK-001, and others.
- NK Cell Therapy Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for NK Cell Therapy Market Drivers and NK Cell Therapy Market Barriers, click here @ NK Cell Therapy Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Natural Killer (NK) cell therapy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- NKTR-214: Nektar therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CellProtect: XNK Therapeutics
- Drug profiles in the detailed report…..
- Early stage products (Phase I/II)
- Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Natural Killer (NK) cell therapy Key Companies
- Natural Killer (NK) cell therapy Key Products
- Natural Killer (NK) cell therapy- Unmet Needs
- Natural Killer (NK) cell therapy- Market Drivers and Barriers
- Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
- Natural Killer (NK) cell therapy Analyst Views
- Natural Killer (NK) cell therapy Key Companies
- Appendix
Got Queries? Find out the related information on NK Cell Therapy Mergers and acquisitions, NK Cell Therapy Licensing Activities @ NK Cell Therapy Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services